26th November 2019, Oxford and Cambridge, United Kingdom
precisionlife and PharmEnable have announced a new drug discovery partnership, collaborating to develop novel treatments for Amyotrophic Lateral Sclerosis (ALS). They are joined by disease researchers at the Sheffield Institute for Translational Neuroscience (SITraN) and neurology experts from Maurice Wohl Clinical Neuroscience Institute (King’s College London).
ALS is a devastating condition that causes the progressive degeneration of nerve cells that control muscle movements. Currently available treatments can help slow down disease progression and control symptoms, but there is no known cure.
precisionlife (formerly known as RowAnalytics), is an innovative Oxford-based AI enabled precision medicine company. It has a world-leading ‘multi-omic’ analysis platform to find and validate new disease targets and stratify patient populations at high-resolution. This scalable, hypothesis-free target validation approach enables the development of novel precision medicine treatments addressing previously unmet medical needs.
Dr Hannah Sore, CEO of PharmEnable, said: “We are delighted to announce the new partnership between PharmEnable and precisionlife. We are impressed with the wealth of experience, novel analytics approaches and systematic disease insights that precisionlife brings to target discovery and validation. Through this partnership, we will be able to develop novel treatments addressing new targets for otherwise devastating conditions.”
PharmEnable is a Cambridge-based drug discovery company, using a combination of medicinal chemistry and AI approaches to design the next generation of specific and cost-effective small molecule drugs. PharmEnable predicts novel small molecules with complex, nature-like 3D structures, and uses computational methods to find hits for disease targets in conditions such as ALS.
Dr Steve Gardner, CEO of precisionlife, said: “Our partnership with PharmEnable brings together evidence-led innovation in targets and small molecule leads for complex diseases. We believe that through our partnership with PharmEnable, we will be able to develop a number of effective new medicines, and we aim to create new options for patients with ALS.”
They are joined by academic partners Professor Ammar Al-Chalabi from King’s College London, and Dr Laura Ferraiuolo at the Sheffield Institute for Translational Neuroscience (SITraN), world leading experts in the neurobiology of ALS.
With this partnership, precisionlife and PharmEnable bring an innovative data-driven approach to drug discovery, aiming to discover a novel treatment for ALS. The partnership will expand to cover other disease areas in the future.
For more information, contact:
Dr Jelena Aleksic, CBO, PharmEnable, firstname.lastname@example.org, (+44) 7793534121
Dr Steve Gardner, CEO, precisionlife, email@example.com, +44 (0) 1865 575 170
PharmEnable (www.pharmenable.com) is a Cambridge (UK) based drug discovery company, using a combination of medicinal chemistry and AI computational approaches to design the next generation of specific and cost-efficient small molecule drugs. Our mission is to discover new treatments for otherwise undruggable conditions.
After nearly dying from antibiotic-resistant sepsis, CEO Dr Hannah Sore left her consulting career behind, instead dedicating herself to creating new medicines. The PharmEnable method focuses on creating chemical diversity, making potential new medicines that are 3-dimensional and nature-like.
This innovative approach has all the advantages of small molecule drugs – the molecules can be produced cost efficiently in large quantities, and taken by patients orally. In addition, the 3D structures make the molecules more specific and less likely to be toxic, and open up new possibilities for treating otherwise undruggable conditions.
For more information, visit www.pharmenable.com.
precisionlife is an innovative Oxford-based AI enabled precision medicine company. We specialise in using AI computational approaches to find associations across large and complex ‘multi-omic’ (genomic, transriptomic, proteomic) data sets . Our aim is to enable new precision medicine discoveries through the application of advanced data science.
Our data platform enables us to find new insights about disease risk, therapy response, and identify new druggable targets across a range of disease conditions. We also use our platform to stratify patient populations, enabling a precision medicine approach to previously untreatable conditions, and improving the probability of drug development success.
precisionlife’s innovative tools enable the personalization at scale required to deliver next generation precision medicine. Led by CEO Dr Steve Gardner, precisionlife was founded by a diverse team of highly experienced life science, healthcare, AI and computer science experts.
For more information, visit www.precisionlife.com.
About our collaborators
Professor Ammar Al-Chalabi at King’s College London is Professor of Neurology and Complex Disease Genetics, and also a Consultant Neurologist. He is the Director of a Care and Research Centre at King’s for ALS patients, and brings a wealth of research and clinical experience focusing on the neurology of ALS.
Dr Laura Ferraiuolo at the Sheffield Institute for Translational Neuroscience (SITraN) is a Reader in Translational Neurobiology. She is an expert at using biological models of ALS and other neurodegenerative diseases to dissect the disease pathways and develop new treatments.